Year All202420232022202120202019 Dec 13, 2024 Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nov 26, 2024 Aligos Therapeutics to Present at Investor Conferences in December Nov 19, 2024 Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024 Nov 06, 2024 Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results Oct 30, 2024 Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024 Oct 22, 2024 Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184 Oct 15, 2024 Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024 Oct 11, 2024 Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Oct 01, 2024 Aligos Therapeutics Appoints David Perry as Vice President of Business Development Sep 30, 2024 Aligos Therapeutics to Present at Investor Conferences in October
Nov 06, 2024 Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
Oct 15, 2024 Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024
